Press Releases Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
18.18 ^USD	+1.62%		+2.83%	+66.18%

May. 10	Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating	MT
May. 09	Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024	May. 13	AQ
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024	May. 10	BU
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 09	BU
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors	May. 07	BU
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy	May. 07	AQ
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)	May. 06	BU
Edgewise Receives European Medicines Agency Orphan Drug Designations for Sevasemten for the Treatment of Becker and Duchenne Muscular Dystrophies	Apr. 24	AQ
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies	Apr. 23	BU
Edgewise Therapeutics : EDG-5506 ARCH 2 YR Topline Results	Apr. 18	PU
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten in Adults with Becker Muscular Dystrophy	Apr. 16	AQ
Edgewise Therapeutics : EDG-5506 ARCH 2 YR Topline Results April 2024	Apr. 15	PU
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)	Apr. 15	BU
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	Mar. 28	BU
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024	Mar. 27	BU
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024	Mar. 05	BU
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference	Feb. 28	BU
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	Feb. 22	BU
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy	Feb. 14	AQ
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)	Feb. 13	BU
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock	Jan. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Press Releases

Filters